Published in J Hepatol on May 31, 2010
Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med (2014) 1.22
Griffithsin has antiviral activity against hepatitis C virus. Antimicrob Agents Chemother (2011) 1.14
Efficient genetic manipulation of the NOD-Rag1-/-IL2RgammaC-null mouse by combining in vitro fertilization and CRISPR/Cas9 technology. Sci Rep (2014) 1.09
Hepatitis C virus infection and related liver disease: the quest for the best animal model. Front Microbiol (2013) 0.99
Engrafted human stem cell-derived hepatocytes establish an infectious HCV murine model. J Clin Invest (2014) 0.97
Experimental models and therapeutic approaches for HBV. Semin Immunopathol (2012) 0.95
Chimeric mouse model for the infection of hepatitis B and C viruses. PLoS One (2013) 0.89
A novel mouse model for stable engraftment of a human immune system and human hepatocytes. PLoS One (2015) 0.84
Visualizing hepatitis C virus infection in humanized mice. J Immunol Methods (2014) 0.82
Hepatitis E Virus (HEV) Genotype 3 Infection of Human Liver Chimeric Mice as a Model for Chronic HEV Infection. J Virol (2016) 0.79
Modeling hepatitis B virus infection, immunopathology and therapy in mice. Antiviral Res (2015) 0.79
Construction of a single lentiviral vector containing tetracycline-inducible Alb-uPA for transduction of uPA expression in murine hepatocytes. PLoS One (2013) 0.78
Liver immune-pathogenesis and therapy of human liver tropic virus infection in humanized mouse models. J Gastroenterol Hepatol (2013) 0.78
Molecular detection and quantification of Plasmodium falciparum-infected human hepatocytes in chimeric immune-deficient mice. Malar J (2013) 0.78
Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells. J Hepatol (2016) 0.76
Host and viral determinants for engraftment of virus permissive human hepatocytes into chimeric immunodeficient mice. J Hepatol (2010) 0.76
Transplantation of human cells in the peritoneal cavity of immunodeficient mice for rapid assays of hepatitis B virus replication. Xenotransplantation (2011) 0.76
Usage of adenovirus expressing thymidine kinase mediated hepatocellular damage for enabling mouse liver repopulation with allogenic or xenogenic hepatocytes. PLoS One (2013) 0.75
Recapitulation of treatment response patterns in a novel humanized mouse model for chronic hepatitis B virus infection. Virology (2016) 0.75
Sodium taurocholate cotransporting polypeptide inhibition efficiently blocks hepatitis B virus spread in mice with a humanized liver. Sci Rep (2016) 0.75
Proteomic approaches to analyzing hepatitis C virus biology. Proteomics (2015) 0.75
Interferon-alpha treatment rapidly clears Hepatitis E virus infection in humanized mice. Sci Rep (2017) 0.75
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology (2004) 6.14
Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell (2007) 5.91
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet (2007) 4.84
Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat Med (2012) 3.96
Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology (2005) 3.72
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med (2007) 3.72
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology (2014) 3.23
Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med (2010) 3.09
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology (2008) 3.09
Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. J Hepatol (2013) 2.98
Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut (2010) 2.91
The onecut transcription factor HNF6 is required for normal development of the biliary tract. Development (2002) 2.89
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology (2008) 2.80
Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol (2002) 2.65
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology (2011) 2.63
Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology (2006) 2.61
Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 2.51
Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology (2012) 2.49
Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology (2008) 2.40
Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest (2005) 2.20
Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. J Clin Invest (2007) 2.19
Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One (2008) 2.18
Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology (2010) 2.13
Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome. Radiology (2013) 2.12
Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut (2013) 2.10
Minimally invasive liver surgery for metastases from colorectal cancer: oncologic outcome and prognostic factors. Surg Endosc (2012) 2.04
The β-adrenoceptor agonist isoproterenol rescues acetaminophen-injured livers through increasing progenitor numbers by Wnt in mice. Hepatology (2014) 2.03
An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis (2008) 2.01
Endoscopic resection of ampullary lesions: a single-center 8-year retrospective cohort study of 91 patients with long-term follow-up. Surg Endosc (2013) 2.01
Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology (2004) 2.01
Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology (2010) 1.98
A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. J Virol Methods (2003) 1.96
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis (2013) 1.95
The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology (2011) 1.94
Progenitor cells in diseased human liver. Semin Liver Dis (2003) 1.93
Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol (2006) 1.89
Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant. J Virol (2007) 1.87
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut (2012) 1.86
External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol (2013) 1.84
Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology (2008) 1.82
Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol (2009) 1.82
High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. J Pathol (2003) 1.80
Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology (2003) 1.79
Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl (2002) 1.79
Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology (2009) 1.76
Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). Hepatology (2015) 1.74
Hepatic progenitor cells in human liver diseases. Semin Cell Dev Biol (2002) 1.74
A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology (2003) 1.73
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology (2011) 1.70
Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut (2014) 1.70
Topography of the vanilloid receptor in the human bladder: more than just the nerve fibers. J Urol (2002) 1.69
Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol (2007) 1.68
A randomized comparison of electrocautery incision with Savary bougienage for relief of anastomotic gastroesophageal strictures. Gastrointest Endosc (2009) 1.66
Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology (2011) 1.65
Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer (2002) 1.65
The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest (2005) 1.63
Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol (2006) 1.60
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology (2004) 1.59
A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. Hepatology (2005) 1.59
Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl (2010) 1.59
Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? Hepatology (2013) 1.57
Hepatocyte-specific IKK gamma/NEMO expression determines the degree of liver injury. Gastroenterology (2007) 1.57
Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology (2004) 1.57
Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog (2009) 1.56
Endoscopic treatment of esophagogastric variceal bleeding in patients with noncirrhotic extrahepatic portal vein thrombosis: a long-term follow-up study. Gastrointest Endosc (2008) 1.56
Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology (2008) 1.56
Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology (2008) 1.55
A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol (2010) 1.54
Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol (2006) 1.54
The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology (2011) 1.52
Silencing of caspase-8 in murine hepatocellular carcinomas is mediated via methylation of an essential promoter element. Gastroenterology (2005) 1.51
Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses. J Hepatol (2004) 1.51
Update on PADI trial: percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia. J Vasc Surg (2009) 1.51
Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res (2009) 1.50
The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine. J Hepatol (2002) 1.48
uPA+/+-SCID mouse with humanized liver as a model for in vivo metabolism of exogenous steroids: methandienone as a case study. Clin Chem (2009) 1.48
Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology (2009) 1.45
Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling. Gut (2009) 1.44